AstraZeneca
Foundation Medicine Nets FDA Approval for Tissue, Liquid NGS CDx for Lynparza Combo
The FDA approved FoundationOne CDx and FoundationOne Liquid for identifying BRCA1/2-mutated mCRPC patients eligible for Lynparza, Zytiga, and a steroid.
Qiagen, AstraZeneca Expand CDx Collaboration Beyond Cancer
Under the agreement, Qiagen will develop and validate a genotyping assay using its QiaStat-Dx platform.
Io9 AI-Driven Digital Pathology Test Shows Potential to Inform Breast, Ovarian Cancer Therapy
Premium
The firm hopes to develop its DeepHRD digital pathology test as an alternative to costly companion diagnostics based on next-generation sequencing.
Angle to Develop Prostate Cancer Liquid Biopsy Assay for AstraZeneca
The company will use its Parsortix platform to develop a circulating tumor cell-based assay to measure androgen receptor status in therapy response.
Circulating Tumor Cell Capture Chip Could Help Predict Therapy Benefit in Lung Cancer Patients
Premium
The new microfluidic chip is designed to capture more circulating tumor cells in patients with non-small cell lung cancer than currently available technologies.
Jun 24, 2022
Almac, AstraZeneca Strike CDx Development Pact
Jun 22, 2022